Ladenburg Thalmann Downgrades Myriad Genetics (MYGN) to Sell
- Record-setting rally pushes on as S&P ends week up 3 percent
- Trump's Cohn Pick Most Bullish Sign Yet for Banks - Cowen
- Unusual 11 Mid-Day Movers: (IDXG) (INVN) (EBS) Higher; (SCON) (DTEA) (DLTH) Lower (more...)
- 21st Century Fox (FOXA) offers to acquire Sky for GBP10.75/share
- Coca Cola (KO) Announces James Quincey to Succeed Muhtar Kent as CEO; Kent to Continue as Chairman
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Ladenburg Thalmann downgraded Myriad Genetics (NASDAQ: MYGN) from Neutral to Sell with a price target of $16.00.
Shares of Myriad Genetics closed at $21.35 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Piper Jaffray Downgrades Allison Transmission (ALSN) to Underweight
- UPDATE: Stifel Downgrades EMCOR Group (EME) to Hold
- Argus Downgrades Sonoco Products (SON) to Hold
Create E-mail Alert Related CategoriesDowngrades, Hot Downgrades
Related EntitiesLadenburg Thalmann Financial Services
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!